Scarica l'app Stockscreener
149.22
4.39%
6.28
Dopo l'orario di chiusura:
151.00
1.78
+1.19%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GH Giù?
Forum
Previsione
Precedente Chiudi:
$142.94
Aprire:
$145.61
Volume 24 ore:
18.77M
Relative Volume:
7.47
Capitalizzazione di mercato:
$19.79B
Reddito:
$1.08B
Utile/perdita netta:
$-433.19M
Rapporto P/E:
-43.88
EPS:
-3.4004
Flusso di cassa netto:
$-225.09M
1 W Prestazione:
+13.23%
1M Prestazione:
+24.51%
6M Prestazione:
+44.90%
1 anno Prestazione:
+198.26%
Intervallo 1D:
$144.27
$151.85
Intervallo di 1 settimana:
$125.12
$151.85
Portata 52W:
$40.35
$151.85
Guardant Health Inc Stock (GH) Company Profile
Nome
Guardant Health Inc
Settore
Industria
Telefono
855-698-8887
Indirizzo
3100 HANOVER STREET, PALO ALTO
Compare GH vs TMO, DHR, IDXX, A, NTRA
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
149.22 | 18.95B | 1.08B | -433.19M | -225.09M | -3.4004 |
TMO
Thermo Fisher Scientific Inc
|
513.03 | 187.95B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
196.19 | 136.75B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
551.50 | 43.78B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
136.01 | 38.27B | 7.23B | 1.41B | 1.09B | 4.979 |
NTRA
Natera Inc
|
261.91 | 37.34B | 2.50B | -226.32M | 71.51M | -1.6412 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-20 | Reiterato | Canaccord Genuity | Buy |
| 2026-02-17 | Iniziato | Robert W. Baird | Outperform |
| 2026-01-05 | Downgrade | Evercore ISI | Outperform → In-line |
| 2025-12-02 | Ripresa | Morgan Stanley | Overweight |
| 2025-09-25 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-09-22 | Ripresa | Wells Fargo | Overweight |
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-01-23 | Iniziato | Barclays | Overweight |
| 2024-06-28 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-04-24 | Ripresa | Craig Hallum | Buy |
| 2023-12-14 | Iniziato | Guggenheim | Neutral |
| 2023-12-13 | Iniziato | Wolfe Research | Peer Perform |
| 2023-11-13 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-09-27 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-05-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-05-05 | Iniziato | UBS | Buy |
| 2023-03-09 | Downgrade | Citigroup | Buy → Neutral |
| 2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
| 2022-11-01 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-10-19 | Iniziato | Craig Hallum | Buy |
| 2022-10-06 | Iniziato | Stephens | Overweight |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-06-03 | Iniziato | Piper Sandler | Overweight |
| 2022-04-28 | Ripresa | BTIG Research | Buy |
| 2022-02-24 | Reiterato | Canaccord Genuity | Buy |
| 2022-02-24 | Reiterato | Citigroup | Buy |
| 2022-02-24 | Reiterato | Cowen | Outperform |
| 2022-02-24 | Reiterato | Morgan Stanley | Overweight |
| 2022-02-24 | Reiterato | SVB Leerink | Outperform |
| 2022-02-24 | Reiterato | Stifel | Buy |
| 2022-02-24 | Reiterato | Wells Fargo | Overweight |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-06-15 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-03 | Iniziato | Goldman | Buy |
| 2021-05-25 | Iniziato | Wells Fargo | Overweight |
| 2021-01-11 | Iniziato | Stifel | Buy |
| 2020-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2020-06-12 | Iniziato | BTIG Research | Buy |
| 2020-02-21 | Iniziato | Guggenheim | Buy |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-08-07 | Reiterato | Canaccord Genuity | Buy |
| 2019-04-16 | Iniziato | Canaccord Genuity | Buy |
| 2019-04-10 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-02-28 | Reiterato | BofA/Merrill | Neutral |
| 2018-10-29 | Iniziato | BofA/Merrill | Neutral |
| 2018-10-29 | Iniziato | JP Morgan | Overweight |
| 2018-10-29 | Iniziato | William Blair | Outperform |
Mostra tutto
Guardant Health Inc Borsa (GH) Ultime notizie
Why Are Guardant Health (GH) Shares Soaring Today - Yahoo Finance
GH (NASDAQ: GH) insider AmirAli Talasaz sells 260,000 shares totaling $28.1M - Stock Titan
[144] Guardant Health, Inc. SEC Filing - Stock Titan
Guardant Health, Inc. Actuals & Estimates (DUS:5GH) - TradingView
Understanding the Setup: (GH) and Scalable Risk - Stock Traders Daily
GH Reinstated by Bernstein -- Price Target Announced at $175 - GuruFocus
5GH Forecast — Price Target — Prediction for 2027 - TradingView
Bernstein upgrades Guardant Health stock rating on FDA approval impact By Investing.com - Investing.com Canada
Guardant Health (GH) Receives Outperform Rating and $175 Price T - GuruFocus
Guardant Health, Inc. Actuals & Estimates (LS:A2N5RY) - TradingView
This Men’s Health Month, a FDA-Approved Blood Test for Colorectal Cancer Offers Men an Easier Way to Screen in Nevada - Nevada Business Magazine
Form 144 Guardant Health For: 24 June By Investing.com - Investing.com South Africa
Guardant Health stock hits 52-week high at 135.89 USD - Investing.com UK
Affiliate sells 2,000 shares via cashless exercise — Guardant Health (NASDAQ: GH) - Stock Titan
Guardant Health stock climbs as investors continue to digest screening and diagnostics catalysts - Quiver Quantitative
GH Maintained by Barclays -- Price Target Raised to $150 - GuruFocus
Guardant Health stock hits 52-week high at 135.89 USD By Investing.com - Investing.com Australia
Insider Sell Alert: Musa Tariq Sells Shares of Guardant Health I - GuruFocus
Guardant Health director Myrtle Potter sells $204,084 in stock By Investing.com - Investing.com Australia
Guardant Health director Tariq Musa sells $255,893 in stock - Investing.com UK
Guardant Health director Myrtle Potter sells $204,084 in stock - Investing.com UK
Form 4 Guardant Health Inc For: 23 June By Investing.com - Investing.com Australia
Guardant Health director Tariq Musa sells $255,893 in stock By Investing.com - Investing.com Nigeria
Guardant Health (GH) director sells 1,951 shares in open-market trade - Stock Titan
Guardant Health (GH) director trims holdings with 1,556-share sale - Stock Titan
Guardant Health (GH) director exercises RSUs, acquires 528 common shares - Stock Titan
Form 144 Guardant Health For: 22 June By Investing.com - Investing.com Australia
Form 4 Guardant Health Inc For: 22 June By Investing.com - Investing.com Australia
Guardant Health (GH) director adds 4,203 shares and receives 2,711 RSUs - Stock Titan
Guardant Health (GH) director exercises 4,203 RSUs and receives 2,711-unit grant - Stock Titan
Guardant Health (GH) director Mignone exercises 4,203 RSUs and receives 2,711-unit grant - Stock Titan
Guardant Health (NASDAQ: GH) director gains shares as 4,203 RSUs vest and 2,711 new units granted - Stock Titan
Guardant Health (GH) director Meghan Joyce gains 4,203 shares from RSU vesting - Stock Titan
Guardant Health (GH) director exercises 4,435 RSUs and receives 2,711-unit award - Stock Titan
Guardant Health (GH) director reports RSU vesting, 5,092 shares and new 2,711 RSU grant - Stock Titan
Director Azar Alex M II receives 2,711 RSUs at Guardant Health (GH) - Stock Titan
Guardant Health Inc Azioni (GH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.76%
0.62%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):